istock-956478432_patricia-dallaire
Patricia-Dallaire / iStockphoto.com
31 May 2018AsiaArchana Shanker and Nupur Maithani

Uncertain times for antibodies in India

Subject matter patentability and sufficiency requirements are issues that are dealt with at the Indian Patent Office (IPO). Issues/challenges relating to these aspects often go unnoticed unless there is an opposition involved. Here we are writing about trends in India in relation to antibodies. The increase in investment in research in the fields of biotechnology and antibodies, in particular, has led to an increase in filing of patent applications related to antibodies.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Asia
20 May 2026   Backed by the country’s wider AI ambitions, Google has signed a deal to roll out healthcare, scientific research, and safety initiatives.
Asia
31 March 2026   The clash between one of India’s largest B2B marketplaces and the country’s drugs regulator challenges the “passive” position of such platforms with regards to allegedly unlawful pharmaceutical listings, says Aarti Aggarwal of Remfry & Sagar.
Asia
20 March 2026   As the patent protecting semaglutide—the drug that made Novo Nordisk one of Europe's most valuable companies—expires in ten countries, the pressure mounts for prices and market leaders alike.